Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer

(2015) Seiji Mabuchi et al.   GYNECOLOGIC ONCOLOGY

Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer

(2015) Janet Mendonca et al.   Oncotarget

PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer

(2014) HaiXia Li et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

RSF1 Is a Positive Regulator of NF-κB–Induced Gene Expression Required for Ovarian Cancer Chemoresistance

(2014) Yeong-In Yang et al.   CANCER RESEARCH

Nuclear Trafficking in Health and Disease

(2014) Amir Mor et al.   CURRENT OPINION IN CELL BIOLOGY

SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agents

(2014) John Gerecitano   Journal of Hematology & Oncology

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

(2014) Kaushal Parikh et al.   Journal of Hematology & Oncology

Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1

(2014) Xuejiao Liu et al.   JOURNAL OF NEURO-ONCOLOGY

CRM1 Is a Direct Cellular Target of the Natural Anti-cancer Agent Plumbagin

(2014) Xuejiao Liu et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Atomic basis of CRM1-cargo recognition, release and inhibition

(2014) Ho Yee Joyce Fung et al.   SEMINARS IN CANCER BIOLOGY

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

(2014) Joel G. Turner et al.   SEMINARS IN CANCER BIOLOGY

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Knockdown of CRM1 inhibits the nuclear export of p27Kip1 phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer

(2013) You Wang et al.   CANCER LETTERS

Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity

(2013) S. McWhinney-Glass et al.   CLINICAL CANCER RESEARCH

Fibroblast Growth Factor 2 Induces E-Cadherin Down-Regulation via PI3K/Akt/mTOR and MAPK/ERK Signaling in Ovarian Cancer Cells

(2013) Man-Tat Lau et al.   PLoS One

Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1

(2013) Qingxiang Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tautomycetin Induces Apoptosis by Inactivating Akt Through a PP1-Independent Signaling Pathway in Human Breast Cancer Cells

(2012) Mingshan Niu et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

High-grade serous ovarian cancer arises from fallopian tube in a mouse model

(2012) J. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma

(2011) R. Wu et al.   CLINICAL CANCER RESEARCH

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

(2011) Kian Behbakht et al.   GYNECOLOGIC ONCOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results

(2011) Gooitzen M van Dam et al.   NATURE MEDICINE

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers

(2008) T Goto et al.   BRITISH JOURNAL OF CANCER

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER

CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer

(2008) Joel Turner et al.   CURRENT MEDICINAL CHEMISTRY